Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)

NCT07183878 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

138

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
High-Risk Acute Myeloid Leukemia
Myelodysplastic Syndromes
High-Risk Myelodysplastic Syndromes

Interventions

DRUG: Venetoclax
OTHER: None-placebo

Sponsor

First Affiliated Hospital of Zhejiang University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]